HRP20190687T1 - N-acetilcisteinske tablete za gutanje - Google Patents
N-acetilcisteinske tablete za gutanje Download PDFInfo
- Publication number
- HRP20190687T1 HRP20190687T1 HRP20190687TT HRP20190687T HRP20190687T1 HR P20190687 T1 HRP20190687 T1 HR P20190687T1 HR P20190687T T HRP20190687T T HR P20190687TT HR P20190687 T HRP20190687 T HR P20190687T HR P20190687 T1 HRP20190687 T1 HR P20190687T1
- Authority
- HR
- Croatia
- Prior art keywords
- tablet
- group
- acetylcysteine
- amount
- tablet according
- Prior art date
Links
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 title claims 9
- 229960004308 acetylcysteine Drugs 0.000 title claims 9
- 239000000314 lubricant Substances 0.000 claims 7
- 239000011230 binding agent Substances 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 229920000881 Modified starch Polymers 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 229960000913 crospovidone Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 claims 2
- -1 disintegrators Substances 0.000 claims 2
- 238000007908 dry granulation Methods 0.000 claims 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 230000009747 swallowing Effects 0.000 claims 2
- 239000000454 talc Substances 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000004368 Modified starch Substances 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 229960004977 anhydrous lactose Drugs 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims 1
- 229940038472 dicalcium phosphate Drugs 0.000 claims 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (12)
1. Tableta za gutanje koja obuhvaća N-acetilcistein od najmanje 80% po masi i najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo odabrano iz skupine koju čine veziva, razrjeđivači, dezintegratori, maziva i klizna sredstva, naznačena time, da se navedena tableta proizvodi uporabom granulata pripravljenog putem postupka suhe granulacije samog N-acetilcisteina, te time, da navedena tableta obuhvaća granulat od samog N-acetilcisteina, najmanje jedno vezivo u količini od 5% ili više, najmanje jedan razrjeđivač u količini od 5% ili više, najmanje jedan dezintegrator u količini od 5% ili više, najmanje jedno mazivo u količini od 1% ili manje, najmanje jedno klizno sredstvo u količini od 1% ili manje, po masi u odnosu na ukupnu masu tablete.
2. Tableta prema zahtjevu 1, naznačena time, da su navedena veziva odabrana iz skupine koju čine hidroksipropilceluloza (HPC), hidroksipropilmetilceluloza (HPMC), polietilenglikol (PEG), metilceluloza (MC), povidon (PVP), modificirane škrobne tvari i ostalo.
3. Tableta prema zahtjevu 1, naznačena time, da su navedeni dezintegratori odabrani iz skupine koju čine krospovidon, natrij-kroskarmeloza, natrijev škrobni glikolat, djelomično predželatinizirani škrob i ostali.
4. Tableta prema zahtjevu 1, naznačena time, da su navedena maziva odabrana iz skupine koju čine Ca-stearat, Mg-stearat, natrijev stearilfumarat, stearinska kiselina i ostalo.
5. Tableta prema zahtjevu 1, naznačena time, da su navedena klizna sredstva odabrana iz skupine koju čine bezvodni koloidni silicijev dioksid, talk i ostalo.
6. Tableta prema zahtjevu 1, naznačena time, da su navedeni razrjeđivači odabrani iz skupine koju čine mikrokristalna celuloza (MCC), bezvodna laktoza ili monohidrat laktoze, predželatinizirani škrob, manitol, izomaltoza, sorbitol i slični ugljikohidrati, bezvodni dikalcijev fosfat ili dikalcijev fosfat-dihidrat, maltodekstrin i ostali.
7. Tableta prema zahtjevu 1, naznačena time, da navedena tableta obuhvaća najmanje jedno vezivo odabrano iz skupine koju čine hidroksipropilceluloza, hidroksipropilmetilceluloza ili polietilenglikol; najmanje jedan razrjeđivač odabran iz skupine koju čine mikrokristalna celuloza, manitol, izomaltoza ili sorbitol; najmanje jedan dezintegrator odabran iz skupine koju čine krospovidon ili natrij-kroskarmeloza; najmanje jedno mazivo odabrano iz skupine koju čine Ca-stearat, Mg-stearat, natrijev stearilfumarat; te najmanje jedno klizno sredstvo odabrano iz skupine koju čine bezvodni koloidni silicijev dioksid ili talk.
8. Tableta prema bilo kojem od prethodnih zahtjeva, naznačena time, da navedena tableta obuhvaća količinu N-acetilcisteina u iznosu između 400 mg i 600 mg.
9. Tableta prema zahtjevu 8, naznačena time, da navedena tableta obuhvaća količinu od 600 mg N-acetilcisteina.
10. Tableta prema zahtjevu 8 ili 9, naznačena time, da se upotrebljava kod pacijenata koji pate od CB (kronični bronhitis) i/ili COPD (kronična opstrukcijska plućna bolest).
11. Tableta prema zahtjevu 10, naznačena time, da su navedeni pacijenti ženskog spola.
12. Postupak proizvodnje tablete za gutanje prema zahtjevu 1, naznačen time, da navedeni postupak obuhvaća (a) fazu granulacije u kojoj se dobiva granulat
N-acetilcisteina putem suhe granulacije samog N-acetilcisteina, (b) fazu miješanja
u kojoj se granulat N-acetilcisteina koji je dobiven u fazi (a), miješa s navedenim
vezivima, razrjeđivačima, dezintegratorima, mazivima i kliznim sredstvima, i (c) faza stlačivanja u kojoj se dobivena smjesa iz faze (b) stlačuje u kompresoru za tabletiranje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000874A ITMI20130874A1 (it) | 2013-05-29 | 2013-05-29 | Compresse deglutibili di n-acetilcisteina |
| PCT/EP2014/060950 WO2014191410A1 (en) | 2013-05-29 | 2014-05-27 | Swallowable n-acetylcysteine tablets |
| EP14728495.4A EP3003278B1 (en) | 2013-05-29 | 2014-05-27 | Swallowable n-acetylcysteine tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190687T1 true HRP20190687T1 (hr) | 2019-06-14 |
Family
ID=48748383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190687TT HRP20190687T1 (hr) | 2013-05-29 | 2019-04-11 | N-acetilcisteinske tablete za gutanje |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9808427B2 (hr) |
| EP (1) | EP3003278B1 (hr) |
| JP (1) | JP6438013B2 (hr) |
| CN (1) | CN105228595B (hr) |
| AU (1) | AU2014273148B2 (hr) |
| BR (1) | BR112015029038B1 (hr) |
| CA (1) | CA2911474C (hr) |
| CY (1) | CY1122114T1 (hr) |
| DK (1) | DK3003278T3 (hr) |
| EA (1) | EA031856B1 (hr) |
| ES (1) | ES2721649T3 (hr) |
| HR (1) | HRP20190687T1 (hr) |
| HU (1) | HUE044880T2 (hr) |
| IL (1) | IL242439B (hr) |
| IT (1) | ITMI20130874A1 (hr) |
| LT (1) | LT3003278T (hr) |
| MX (1) | MX366917B (hr) |
| MY (1) | MY174005A (hr) |
| PE (1) | PE20160184A1 (hr) |
| PH (1) | PH12015502608A1 (hr) |
| PL (1) | PL3003278T3 (hr) |
| PT (1) | PT3003278T (hr) |
| RS (1) | RS58653B1 (hr) |
| SG (2) | SG10201709861YA (hr) |
| SI (1) | SI3003278T1 (hr) |
| TR (1) | TR201906101T4 (hr) |
| UA (1) | UA117829C2 (hr) |
| WO (1) | WO2014191410A1 (hr) |
| ZA (1) | ZA201508411B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3554491T3 (pl) * | 2016-12-15 | 2023-07-17 | Zambon S.P.A. | N-acetylocysteina do stosowania jako środek antybakteryjny |
| IT201700109080A1 (it) * | 2017-09-28 | 2019-03-28 | Neilos S R L | Composizione per la prevenzione e/o il trattamento delle affezioni delle vie respiratorie |
| AU2018357886B2 (en) * | 2017-11-02 | 2024-04-18 | Zambon S.P.A. | Pharmaceutical compositions comprising safinamide |
| US10288629B1 (en) * | 2017-12-19 | 2019-05-14 | Aeterna Zentaris, Inc. | Method of assessing growth hormone deficiency in humans by a macimorelin containing composition |
| SG11202010322XA (en) * | 2018-06-14 | 2020-11-27 | Poxel | Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes |
| IT201800007928A1 (it) * | 2018-08-07 | 2020-02-07 | Sofar Spa | Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio |
| CN112843008A (zh) * | 2021-02-07 | 2021-05-28 | 广东赛康制药厂有限公司 | 一种乙酰半胱氨酸片及其制备方法 |
| CN114886860B (zh) * | 2022-06-28 | 2023-04-25 | 山东达因海洋生物制药股份有限公司 | 一种乙酰半胱氨酸药物组合物及其制剂和制备工艺 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2077757T5 (es) * | 1990-10-19 | 2001-06-01 | Spirig Ag Pharmazeutische Prap | Preparacion farmaceutica solida con disolucion rapida que contiene la n-acetilcisteina. |
| GB9305058D0 (en) * | 1993-03-12 | 1993-04-28 | Penn Pharm Ltd | Pharmaceutical compositions |
| IT1311907B1 (it) * | 1999-04-06 | 2002-03-20 | Zambon Spa | Compresse deglutibili ad alto contenuto di n-acetilcisteina. |
| US6623754B2 (en) * | 2001-05-21 | 2003-09-23 | Noveon Ip Holdings Corp. | Dosage form of N-acetyl cysteine |
| JP2003155232A (ja) * | 2001-09-07 | 2003-05-27 | Takeda Chem Ind Ltd | 不快な臭いが低減されたｌ−システイン配合固形製剤およびその製造方法 |
| US20080139654A1 (en) * | 2006-12-09 | 2008-06-12 | Eric Mott Soderling | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
| IT1399492B1 (it) * | 2010-04-13 | 2013-04-19 | Alpex Pharma Sa | Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina. |
| EP2574333B1 (en) | 2011-09-27 | 2017-01-11 | Friulchem SpA | N-acetylcysteine effervescent tablet and its therapeutical applications |
-
2013
- 2013-05-29 IT IT000874A patent/ITMI20130874A1/it unknown
-
2014
- 2014-05-27 EA EA201592172A patent/EA031856B1/ru unknown
- 2014-05-27 LT LTEP14728495.4T patent/LT3003278T/lt unknown
- 2014-05-27 HU HUE14728495 patent/HUE044880T2/hu unknown
- 2014-05-27 EP EP14728495.4A patent/EP3003278B1/en active Active
- 2014-05-27 SG SG10201709861YA patent/SG10201709861YA/en unknown
- 2014-05-27 RS RS20190507A patent/RS58653B1/sr unknown
- 2014-05-27 SG SG11201509177VA patent/SG11201509177VA/en unknown
- 2014-05-27 PE PE2015002421A patent/PE20160184A1/es active IP Right Grant
- 2014-05-27 WO PCT/EP2014/060950 patent/WO2014191410A1/en active Application Filing
- 2014-05-27 TR TR2019/06101T patent/TR201906101T4/tr unknown
- 2014-05-27 PL PL14728495T patent/PL3003278T3/pl unknown
- 2014-05-27 BR BR112015029038-8A patent/BR112015029038B1/pt active IP Right Grant
- 2014-05-27 PT PT14728495T patent/PT3003278T/pt unknown
- 2014-05-27 AU AU2014273148A patent/AU2014273148B2/en active Active
- 2014-05-27 CA CA2911474A patent/CA2911474C/en active Active
- 2014-05-27 US US14/893,100 patent/US9808427B2/en active Active
- 2014-05-27 MY MYPI2015704193A patent/MY174005A/en unknown
- 2014-05-27 DK DK14728495.4T patent/DK3003278T3/da active
- 2014-05-27 SI SI201431172T patent/SI3003278T1/sl unknown
- 2014-05-27 MX MX2015016130A patent/MX366917B/es active IP Right Grant
- 2014-05-27 UA UAA201512351A patent/UA117829C2/uk unknown
- 2014-05-27 JP JP2016516129A patent/JP6438013B2/ja active Active
- 2014-05-27 CN CN201480029563.1A patent/CN105228595B/zh active Active
- 2014-05-27 ES ES14728495T patent/ES2721649T3/es active Active
-
2015
- 2015-11-04 IL IL242439A patent/IL242439B/en active IP Right Grant
- 2015-11-13 ZA ZA2015/08411A patent/ZA201508411B/en unknown
- 2015-11-23 PH PH12015502608A patent/PH12015502608A1/en unknown
-
2019
- 2019-04-11 CY CY20191100404T patent/CY1122114T1/el unknown
- 2019-04-11 HR HRP20190687TT patent/HRP20190687T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190687T1 (hr) | N-acetilcisteinske tablete za gutanje | |
| JP2018507200A5 (hr) | ||
| RU2017133990A (ru) | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона | |
| HRP20201162T1 (hr) | Farmaceutski sastav koji može uključiti lenalidomid u različitim kristaliničnim modifikacijama | |
| HRP20170594T1 (hr) | Farmaceutski pripravci ko-kristala tramadola i koksiba | |
| JP2007523210A5 (hr) | ||
| CA2601955A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| JP2010132654A5 (hr) | ||
| RU2016128216A (ru) | Покрытая пленкой таблетка, содержащая холина альфосцерат, и способ ее изготовления | |
| RU2019132494A (ru) | Фармацевтические таблетки с элтромбопагом оламина | |
| TW201625223A (zh) | 用於口服投藥之包含依澤替米貝（ｅｚｅｔｉｍｉｂｅ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）的複合調配物及其製備方法 | |
| EP3384901A1 (en) | Pharmaceutical composition comprising lenvatinib mesylate | |
| US20130344150A1 (en) | Direct compression tablets of otilonium | |
| CN103211815A (zh) | 一种缬沙坦氨氯地平药物组合物及其制备方法 | |
| KR20110135168A (ko) | 골다공증 예방 또는 치료용 조성물 및 이의 제조방법 | |
| WO2014154643A1 (en) | Extended release formulations of metformin | |
| US20130085145A1 (en) | Imatinib mesilate pharmaceutical tablet | |
| JP6379043B2 (ja) | カンデサルタンシレキセチル含有医薬組成物 | |
| KR100960953B1 (ko) | 습식과립법을 이용한 텔미사르탄 함유 정제의 제조 방법 | |
| WO2017170763A1 (ja) | 崩壊錠及びその製造方法 | |
| JP6565930B2 (ja) | 口腔内崩壊錠の製造方法 | |
| CN104000821B (zh) | 含有替米沙坦和苯磺酸氨氯地平的口服双层片剂及其制备方法 | |
| WO2018104370A1 (en) | Pharmaceutical compositions of dabigatran | |
| RU2013107724A (ru) | Фармацевтические композиции монтелукаста и левоцетиризина | |
| JP2018127417A (ja) | フェブキソスタット含有口腔内崩壊錠 |